1-20 of 146 Search Results for

tgct

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 5193.
Published: 15 June 2022
...Hui Zhang; Da Jiang; Erhong Meng; Wenya Song; Xue Zhang Introduction: To date, very limited information is available about the efficacy of immune checkpoint inhibitor (ICI) therapy in mixed testicular germ cell tumor (TGCT) or variations of DNA damage repair (DDR) genes as predicators for it. Case...
Images
TET2 opposes ccRCC progression.  A,  Correlation analysis of <em>TET2</em>...
Published: 06 June 2022
Figure 1. TET2 opposes ccRCC progression. A, Correlation analysis of TET2 expression and prognosis of 33 cancer types in TCGA. The vertical dashed line represents HR = 1 and the horizontal dashed line means Q = 0.05. The data were acquired from GEPIA ( 26 ). All 33 cancer types:ACC, BLCA, BRCA, CESC, CHOL, COAD, DLBC, ESCA, GBM, HNSC, KICH, KIRC, KIRP, LAML, LGG, LIHC, LUAD, LUSC, MESO, OV, PAAD, PCPG, PRAD, READ, SARC, SKCM, STAD, TGCT, THCA, THYM, UCEC, UCS, UVM. B, Kaplan–Meier analysis of the correlation of TET2 expression with OS and DFS of patients with ccRCC, respectively. The data were obtained from GEPIA. C, Kaplan–Meier analysis of the correlation of TET2 protein level with OS of patients with ccRCC in the validated cohort (n = 87). All the patients with ccRCC were divided into two groups according to the IHC final scores for TET2 expression. The IHC final scores of tumor samples are 1, 2, 3, 4, 6, respectively. And the samples with scores of 1, 2, 3 were grouped into TET2 low (n = 48), while samples with scores of 4 and 6 were grouped into TET2 high (n = 39). D and E, The correlation analysis of TET2 expression with metastasis ( D ) and stage status ( E ) of patients with ccRCC. The data were downloaded from UCSC Xena ( 27 ). F and G, Cell proliferation ( F ) and colony formation ( G ) assays were performed after transfection with control or TET2 plasmids in ccRCC cells. n = 3. H, The effect of TET2 over expression on tumor growth ccRCC was determined by xenograft. I and J, Tumor volume ( I ) and weight ( J ) were measured, respectively. n = 8 per group. Scale bar, 1 cm. K, Growth curve of ccRCC and HK2 cells was determined after treatment with vitamin C at indicated concentrations. n = 3. χ2 test ( D and E ). Two-tailed Student t test ( F , G , I , and J ). One-way ANOVA ( K ). **, P < 0.01; ****, P < 0.0001. Error bars, ± SD. Con, control; NS, not significant; OD, optical density. Figure 1. TET2 opposes ccRCC progression. A, Correlation analysis of TET2 expression and prognosis of 33 cancer types in TCGA. The vertical dashed line represents HR = 1 and the horizontal dashed line means Q = 0.05. The data were acquired from GEPIA (26). All 33 cancer types:ACC, BLCA, BRCA, CESC, CHOL, COAD, DLBC, ESCA, GBM, HNSC, KICH, KIRC, KIRP, LAML, LGG, LIHC, LUAD, LUSC, MESO, OV, PAAD, PCPG, PRAD, READ, SARC, SKCM, STAD, TGCT, THCA, THYM, UCEC, UCS, UVM. B, Kaplan–Meier analysis of the correlation of TET2 expression with OS and DFS of patients with ccRCC, respectively. The data were obtained from GEPIA. C, Kaplan–Meier analysis of the correlation of TET2 protein level with OS of patients with ccRCC in the validated cohort (n = 87). All the patients with ccRCC were divided into two groups according to the IHC final scores for TET2 expression. The IHC final scores of tumor samples are 1, 2, 3, 4, 6, respectively. And the samples with scores of 1, 2, 3 were grouped into TET2 low (n = 48), while samples with scores of 4 and 6 were grouped into TET2 high (n = 39). D and E, The correlation analysis of TET2 expression with metastasis (D) and stage status (E) of patients with ccRCC. The data were downloaded from UCSC Xena (27). F and G, Cell proliferation (F) and colony formation (G) assays were performed after transfection with control or TET2 plasmids in ccRCC cells. n = 3. H, The effect of TET2 over expression on tumor growth ccRCC was determined by xenograft. I and J, Tumor volume (I) and weight (J) were measured, respectively. n = 8 per group. Scale bar, 1 cm. K, Growth curve of ccRCC and HK2 cells was determined after treatment with vitamin C at indicated concentrations. n = 3. χ2 test (D and E). Two-tailed Student t test (F, G, I, and J). One-way ANOVA (K). **, P < 0.01; ****, P < 0.0001. Error bars, ± SD. Con, control; NS, not significant; OD, optical density. More
Journal Articles
Cancer Res (2022) 82 (11): 2097–2109.
Published: 06 June 2022
... types:ACC, BLCA, BRCA, CESC, CHOL, COAD, DLBC, ESCA, GBM, HNSC, KICH, KIRC, KIRP, LAML, LGG, LIHC, LUAD, LUSC, MESO, OV, PAAD, PCPG, PRAD, READ, SARC, SKCM, STAD, TGCT, THCA, THYM, UCEC, UCS, UVM. B, Kaplan–Meier analysis of the correlation of TET2 expression with OS and DFS of patients...
Includes: Supplementary data
Journal Articles
Cancer Res (2022) 82 (11): 2076–2083.
Published: 06 June 2022
... clinical trials ( Fig. 3B ; Supplementary Table S6; ref. 13 ). The top-ranked cancer types are TGCT (testicular germ cell tumors, TMB power = 2.95, two times higher than the TMB power observed in lung cancer), DLBC (lymphoid neoplasm diffuse large B-cell lymphoma, TMB power = 2.30, 1.6 times higher than...
Includes: Supplementary data
Journal Articles
Cancer Res (2022) 82 (12): 2226–2238.
Published: 15 June 2022
...), squamous cell carcinoma of the head and neck (HNSCC), ovarian serous cystadenocarcinoma (OV), UCEC, breast invasive carcinoma (BRCA), liver hepatocellular carcinoma (LIHC), rectum adenocarcinoma (READ), testicular germ cell tumors (TGCT), kidney renal papillary cell carcinoma (KIRP)], significantly low...
Includes: Supplementary data
Journal Articles
Cancer Res canres.0225.2022-1-31 22:36:38.487.
Published: 27 May 2022
... between tumors and normal controls. In particular, colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), uterine carcinosarcoma (UCS), breast invasive carcinoma (BRCA), glioblastoma multiforme (GBM), testicular germ cell tumors (TGCT) were significantly distinguished from the control group, implying...
Images
Context-specific regulation of alternative promoters by ncNATs.  A,  Bubble...
Published: 01 December 2021
Figure 7. Context-specific regulation of alternative promoters by ncNATs. A, Bubble plots illustrating all promoter-switch ncNATs identified for each indicated NT tissue (right) or cancer types (left). Qualifying requirements to be classified as a promoter-switch ncNAT include: (i) ncNAT must demonstrate a significant positive or negative correlation with either promoter a or b of its sense gene in NT or tumor samples (defined as "pos and null" and "neg and null," see Fig. 6 ); and (ii) if both promoters (promoter a and b) pass the Wilcoxon test (P < 0.001), the ncNAT is excluded. Magnitude of difference in promoter activity of the indicated sense gene between high-ncNAT and low groups [log2(fold change)] is proportional to the dot size; pink, positive correlation; blue, negative correlation. #, promoter-switch ncNATs identified in both NT tissue and cancer. *2 ncNATs for CHKA (NT): ENSG00000255031 and ENSG00000255236; (ii) ncNATs for SLC25A25 (tumor): ENSG00000234771 and ENSG00000269988. Left axis lists all the included cancer types with following TCGA abbreviations: ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; COAD, colon adenocarcinoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma. B, Bar charts representing the expression levels of ENSG00000255031 (antisense to CHKA) and ENSG00000259357 (antisense to CERS2) in Huh7 cells after treatment with shScr control or shRNAs against the indicated ncNATs. C, Bar charts representing the relative P1 or P2 promoter activity of CHKA or CERS2 in the shRNA-treated cells described in B . qPCR specifically amplifying P1 and P2-derived isoforms were performed for promoter usage measurement. CHKA P1, prmtr.17341; P2, prmtr.17345. CERS2 P1, prmtr.35422; P2, prmtr.35424. Exact genomic coordinates for each promoter are specified in Supplementary Table S1. B and C, Data are presented as the mean ± SEM of triplicates from a representative experiment of two independent experiments (unpaired, two-tailed Student t test; *, P < 0.05; **, P < 0.01; ***, P < 0.001). Figure 7. Context-specific regulation of alternative promoters by ncNATs. A, Bubble plots illustrating all promoter-switch ncNATs identified for each indicated NT tissue (right) or cancer types (left). Qualifying requirements to be classified as a promoter-switch ncNAT include: (i) ncNAT must demonstrate a significant positive or negative correlation with either promoter a or b of its sense gene in NT or tumor samples (defined as "pos and null" and "neg and null," see Fig. 6); and (ii) if both promoters (promoter a and b) pass the Wilcoxon test (P < 0.001), the ncNAT is excluded. Magnitude of difference in promoter activity of the indicated sense gene between high-ncNAT and low groups [log2(fold change)] is proportional to the dot size; pink, positive correlation; blue, negative correlation. #, promoter-switch ncNATs identified in both NT tissue and cancer. *2 ncNATs for CHKA (NT): ENSG00000255031 and ENSG00000255236; (ii) ncNATs for SLC25A25 (tumor): ENSG00000234771 and ENSG00000269988. Left axis lists all the included cancer types with following TCGA abbreviations: ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; COAD, colon adenocarcinoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma. B, Bar charts representing the expression levels of ENSG00000255031 (antisense to CHKA) and ENSG00000259357 (antisense to CERS2) in Huh7 cells after treatment with shScr control or shRNAs against the indicated ncNATs. C, Bar charts representing the relative P1 or P2 promoter activity of CHKA or CERS2 in the shRNA-treated cells described in B. qPCR specifically amplifying P1 and P2-derived isoforms were performed for promoter usage measurement. CHKA P1, prmtr.17341; P2, prmtr.17345. CERS2 P1, prmtr.35422; P2, prmtr.35424. Exact genomic coordinates for each promoter are specified in Supplementary Table S1. B and C, Data are presented as the mean ± SEM of triplicates from a representative experiment of two independent experiments (unpaired, two-tailed Student t test; *, P < 0.05; **, P < 0.01; ***, P < 0.001). More
Journal Articles
Cancer Res (2021) 81 (23): 5849–5861.
Published: 01 December 2021
... carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma...
Includes: Supplementary data
Images
Cystine transporter SLC7A11 is upregulated in CSLCs.  A,  Correlation betwe...
Published: 15 October 2021
Figure 1. Cystine transporter SLC7A11 is upregulated in CSLCs. A, Correlation between cancer stemness and ferroptosis genes expression in 33 tumor types is shown. The Kruskal test in R was used to test the correlation; P < 0.05 was considered statistically significant. ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma. B, H1299 adherent and oncosphere cells were cultured in different concentrations of cysteine for 24 hours, and cell viability of indicated cells was measured. The data are representative of three independent experiments. C, Gene expression data of CD166 control and CD166+ lung CSLCs were obtained from GEO (GSE33198) and heatmap of ferroptosis-related gene expression is shown. D, Expression levels of SLC7A11 and CD166 in CD166 control cells, CD166+ lung CSLCs, and lung tumor sphere are shown. *, P < 0.05; **, P < 0.01; ***, P < 0.001 (Student t test). E, Expression levels of SLC7A11, SOX2, and CD166 in CD166 versus CD166+ lung tumor cells from TCGA database are shown as dot plots. The data are represented as scatter dot plot and the line shows mean. Significance was assessed by the Wilcoxon test compared between the indicated two groups. ***, P < 0.001 (Student t test). F, SLC7A11 was upregulated in H1299 tumor oncospheres when compared with adherent cells. **, P < 0.01; ***, P < 0.001 (Student t test). G, SLC7A11 but not other transporters was upregulated in SW620 tumor oncospheres when compared with adherent cells. ***, P < 0.001 (Student t test). H, SLC7A11 but not other transporters was upregulated in HCT116 tumor oncospheres when compared with adherent cells. *, P < 0.05; ***, P < 0.001 (Student t test). Figure 1. Cystine transporter SLC7A11 is upregulated in CSLCs. A, Correlation between cancer stemness and ferroptosis genes expression in 33 tumor types is shown. The Kruskal test in R was used to test the correlation; P < 0.05 was considered statistically significant. ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma. B, H1299 adherent and oncosphere cells were cultured in different concentrations of cysteine for 24 hours, and cell viability of indicated cells was measured. The data are representative of three independent experiments. C, Gene expression data of CD166− control and CD166+ lung CSLCs were obtained from GEO (GSE33198) and heatmap of ferroptosis-related gene expression is shown. D, Expression levels of SLC7A11 and CD166 in CD166− control cells, CD166+ lung CSLCs, and lung tumor sphere are shown. *, P < 0.05; **, P < 0.01; ***, P < 0.001 (Student t test). E, Expression levels of SLC7A11, SOX2, and CD166 in CD166− versus CD166+ lung tumor cells from TCGA database are shown as dot plots. The data are represented as scatter dot plot and the line shows mean. Significance was assessed by the Wilcoxon test compared between the indicated two groups. ***, P < 0.001 (Student t test). F, SLC7A11 was upregulated in H1299 tumor oncospheres when compared with adherent cells. **, P < 0.01; ***, P < 0.001 (Student t test). G, SLC7A11 but not other transporters was upregulated in SW620 tumor oncospheres when compared with adherent cells. ***, P < 0.001 (Student t test). H, SLC7A11 but not other transporters was upregulated in HCT116 tumor oncospheres when compared with adherent cells. *, P < 0.05; ***, P < 0.001 (Student t test). More
Journal Articles
Cancer Res (2021) 81 (20): 5217–5229.
Published: 15 October 2021
... adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma. B, H1299 adherent and oncosphere cells were cultured in different concentrations of cysteine for 24 hours, and cell viability...
Includes: Supplementary data
Journal Articles
Cancer Res (2021) 81 (13_Supplement): 2096.
Published: 01 July 2021
...Zeeshan Fazal; Ratnakar Singh; Megan Tomlin; Doha Shokry; Aleyah Hattab; Sarah Spinella; Michael Spinella Acquired resistance to chemotherapy is perhaps the major barrier to cure of advanced cancers. Testicular germ cell tumors (TGCTs) are the most common cancers of young males. TGCTs are one...
Journal Articles
Cancer Res (2021) 81 (13_Supplement): 874.
Published: 01 July 2021
... in the validated genetic predictor of LTL, rs2736100, a variant on TERT, is associated with adult testicular GCT (TGCT); therefore, in our overall analysis, we removed this SNP to avoid violating MR assumptions. Pediatric GCT samples were obtained from a Children's Oncology Group study and state biobank programs...
Journal Articles
Cancer Res (2021) 81 (13_Supplement): 2127.
Published: 01 July 2021
...Ratnakar Singh; Emmanuel Bikorimana; Zeeshan Fazal; Cliff Yerby; Hannah Baldwin; Aleyah Destiny Hattab; Megan Tomlin; Andrea K. Corbet; Raya Iman Boyd; Khadeeja Shahid; Doha Naguib Ahmed Mohamed Shokry; Sarah Joy Spinella; Michael J. Spinella Testicular germ cell tumors (TGCTs) are the most...
Journal Articles
Images
p53/KITLG prosurvival signaling can attenuate responses to p53-activating a...
Published: 01 April 2021
Figure 5. p53/KITLG prosurvival signaling can attenuate responses to p53-activating agents. A, Bar blots of the IC50 values for Nutlin3. P values were calculated using a two-tailed t test and error bars represent SEM in at least three independent biological replicates. B, Western blot analysis of cells that were treated with or without Nutlin3 for 6 hours, lysed and analyzed for p53, acetylated p53, Parp1, and cleaved caspase-3 protein expression. C, Schematic overview for the microscopy-based high-content drug screening. D, Bar plots depicting the number of hits and “non-hits” for each of the 14 drug classes examined. E, Scatter plots of the fold enrichment of hits among each drug class relative to the total compounds in the 14 drug classes. The horizontal dashed lines represent the FDR-adjusted P value of 0.05. F and G, Bar plots of combination indexes of dasatinib with Nutlin3 ( F ) or doxorubicin ( G ) in p53-REs+/+ (gray bars, two clones), p53-REs−/− (red bars, two clones), and KI clones (orange bars, one clone) of TERA1 and TERA2 cells. H, Bar plots of combination indexes of dasatinib with Nutllin3 or doxorubicin in panel of TGCT cell lines. I, Growth curves of 2102EP xenograft tumors treated with vehicle, doxorubicin, dasatinib, or the combination of doxorubicin and dasatinib. Error bars, means ± SEM (n = 6). Figure 5. p53/KITLG prosurvival signaling can attenuate responses to p53-activating agents. A, Bar blots of the IC50 values for Nutlin3. P values were calculated using a two-tailed t test and error bars represent SEM in at least three independent biological replicates. B, Western blot analysis of cells that were treated with or without Nutlin3 for 6 hours, lysed and analyzed for p53, acetylated p53, Parp1, and cleaved caspase-3 protein expression. C, Schematic overview for the microscopy-based high-content drug screening. D, Bar plots depicting the number of hits and “non-hits” for each of the 14 drug classes examined. E, Scatter plots of the fold enrichment of hits among each drug class relative to the total compounds in the 14 drug classes. The horizontal dashed lines represent the FDR-adjusted P value of 0.05. F and G, Bar plots of combination indexes of dasatinib with Nutlin3 (F) or doxorubicin (G) in p53-REs+/+ (gray bars, two clones), p53-REs−/− (red bars, two clones), and KI clones (orange bars, one clone) of TERA1 and TERA2 cells. H, Bar plots of combination indexes of dasatinib with Nutllin3 or doxorubicin in panel of TGCT cell lines. I, Growth curves of 2102EP xenograft tumors treated with vehicle, doxorubicin, dasatinib, or the combination of doxorubicin and dasatinib. Error bars, means ± SEM (n = 6). More
Images
The p53-bound cancer risk locus in <em>KITLG</em> associates with p...
Published: 01 April 2021
Figure 4. The p53-bound cancer risk locus in KITLG associates with patient outcome and attenuates p53′s anticancer activities. A and B, Dot plots showing the enrichment of KITLG copy number gains ( A ) and risk allele frequencies ( B ) across TCGA cancer types. −Log10-adjusted P values are plotted against the log2-fold change of the percentage of tumors with KITLG gains/risk alleles in a given cancer type versus the other cancers combined. C, A Kaplan–Meier survival curve for PFI in patients with p53wt testicular cancer with high or low KITLG mRNA expression. P value was calculated using log-rank test. D, Genetic fine mapping identified six SNPs with the strongest TGCT GWAS signal and that are in high linkage disequilibrium (r2) in Europeans (red square). E, A Kaplan–Meier survival curve for PFI in patients with high-stage p53wt testicular cancer carrying either the risk (orange) or the non-risk allele (gray) of the KITLG risk SNP. F, A diagram of the CRISPR-editing utilized. G,  KITLG gene expression in CRISPR-edited clones using qRT-PCR normalized to GAPDH. In total, two to three clones of each genotype were analyzed in three independent biological replicates. P values were calculated using a one-way ANOVA, followed by Tukey multiple comparison test. H, A bar graph of the fold change in KITLG expression after Nutlin3 treatment. Error bars represent SEM of two clones for each genotype and in two independent experiments. P values were calculated using a two-tailed t test. I, Dot plots of KITLG expression in CRISPR-edited clones. Figure 4. The p53-bound cancer risk locus in KITLG associates with patient outcome and attenuates p53′s anticancer activities. A and B, Dot plots showing the enrichment of KITLG copy number gains (A) and risk allele frequencies (B) across TCGA cancer types. −Log10-adjusted P values are plotted against the log2-fold change of the percentage of tumors with KITLG gains/risk alleles in a given cancer type versus the other cancers combined. C, A Kaplan–Meier survival curve for PFI in patients with p53wt testicular cancer with high or low KITLG mRNA expression. P value was calculated using log-rank test. D, Genetic fine mapping identified six SNPs with the strongest TGCT GWAS signal and that are in high linkage disequilibrium (r2) in Europeans (red square). E, A Kaplan–Meier survival curve for PFI in patients with high-stage p53wt testicular cancer carrying either the risk (orange) or the non-risk allele (gray) of the KITLG risk SNP. F, A diagram of the CRISPR-editing utilized. G, KITLG gene expression in CRISPR-edited clones using qRT-PCR normalized to GAPDH. In total, two to three clones of each genotype were analyzed in three independent biological replicates. P values were calculated using a one-way ANOVA, followed by Tukey multiple comparison test. H, A bar graph of the fold change in KITLG expression after Nutlin3 treatment. Error bars represent SEM of two clones for each genotype and in two independent experiments. P values were calculated using a two-tailed t test. I, Dot plots of KITLG expression in CRISPR-edited clones. More
Journal Articles
Cancer Res (2020) 80 (16_Supplement): 1203.
Published: 15 August 2020
... Wiklund; Tongzhang Zheng; Ewa Rajpert- De Meyts; Stephen Schwartz; Katherine McGlynn; Peter Kanetsky; Katherine Nathanson Background: Testicular germ cell tumors (TGCT) are the most common cancers in young men of European ancestry aged 20 to 39 years. The incidence of TGCT has doubled over the past 20...
Journal Articles
Cancer Res (2020) 80 (16_Supplement): 2020.
Published: 15 August 2020
...Paul Severson; Brian L. West; William D. Tap; Zev A. Wainberg; Sandra Tong-Starksen; Henry H. Hsu; Chao Zhang Background: Tenosynovial giant cell tumors (TGCTs) are characterized by rearrangements of the colony-stimulating factor 1 (CSF1) gene. Dysregulated CSF1 may attract CSF1 receptor (CSF1R...
Journal Articles
Cancer Res (2020) 80 (16_Supplement): 5446.
Published: 15 August 2020
...Paloma Martin-Gimeno; Beatriz Paumard-Hernandez; Oriol Calvete; Javier Benitez Testicular Germ Cell Tumor (TGCT) is the most common cancer type in men between 15-45 years old (1 per 250 men). Around 1-2% of all cases are familial (with at least two affected individuals within the same family...
Journal Articles
Cancer Res (2020) 80 (21): 4854–4867.
Published: 03 November 2020
...; ACC, adrenocortical carcinoma; PCPG, pheochromocytoma and paraganglioma; SARC, sarcoma; LAML, acute myeloid leukemia; PAAD, pancreatic adenocarcinoma; ESCA, esophageal carcinoma; TGCT, testicular germ cell tumors; THYM, thymoma; MESO, mesothelioma; UVM, uveal melanoma; DLBC, lymphoid neoplasm diffuse...
Includes: Supplementary data